Cooperation between Noncanonical Ras Network Mutations

Cell Reports

Volumn 10, Issue 3, 2015, Pages 307-316

  Stites, Edward C ^a,b   Trampont, Paul C ^c   Haney, Lisa B ^c   Walk, Scott F ^c   Ravichandran, Kodi S ^c  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; NEUROFIBROMIN; RAS PROTEIN;

ANIMAL CELL; ARTICLE; CALCULATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENOMIC INSTABILITY; MATHEMATICAL ANALYSIS; MOUSE; NF1 GENE; NONHUMAN; NONSENSE MUTATION; ONCOGENE RAS; POINT MUTATION; PROTEIN DEPLETION; PROTEIN PHOSPHORYLATION; SIMULATION; TUMOR SUPPRESSOR GENE;

EID: 84921365136     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.12.035     Document Type: Article

References (31)

1. Barretina J., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehár J., Kryukov G.V., Sonkin D., et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012, 483:603-607.
2. Beckman R.A., Loeb L.A. Genetic instability in cancer: theory and experiment. Semin. Cancer Biol. 2005, 15:423-435.
3. Benedict K.F., Mac Gabhann F., Amanfu R.K., Chavali A.K., Gianchandani E.P., Glaw L.S., Oberhardt M.A., Thorne B.C., Yang J.H., Papin J.A., et al. Systems analysis of small signaling modules relevant to eight human diseases. Ann. Biomed. Eng. 2011, 39:621-635.
4. Biankin A.V., Waddell N., Kassahn K.S., Gingras M.C., Muthuswamy L.B., Johns A.L., Miller D.K., Wilson P.J., Patch A.M., Wu J., et al. Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes. Nature 2012, 491:399-405. Australian Pancreatic Cancer Genome Initiative.
5. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455:1061-1068. Cancer Genome Atlas Research Network.
6. Chen J., Yue H., Ouyang Q. Correlation between oncogenic mutations and parameter sensitivity of the apoptosis pathway model. PLoS Comput. Biol. 2014, 10:e1003451.
7. Courtois-Cox S., Genther Williams S.M., Reczek E.E., Johnson B.W., McGillicuddy L.T., Johannessen C.M., Hollstein P.E., MacCollin M., Cichowski K. A negative feedback signaling network underlies oncogene-induced senescence. Cancer Cell 2006, 10:459-472.
8. Donovan S., Shannon K.M., Bollag G. GTPase activating proteins: critical regulators of intracellular signaling. Biochim. Biophys. Acta 2002, 1602:23-45.
9. Gaudet S., Spencer S.L., Chen W.W., Sorger P.K. Exploring the contextual sensitivity of factors that determine cell-to-cell variability in receptor-mediated apoptosis. PLoS Comput. Biol. 2012, 8:e1002482.
10. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
11. Hodis E., Watson I.R., Kryukov G.V., Arold S.T., Imielinski M., Theurillat J.P., Nickerson E., Auclair D., Li L., Place C., et al. A landscape of driver mutations in melanoma. Cell 2012, 150:251-263.
12. Johannessen C.M., Boehm J.S., Kim S.Y., Thomas S.R., Wardwell L., Johnson L.A., Emery C.M., Stransky N., Cogdill A.P., Barretina J., et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010, 468:968-972.
13. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., Mankoo P., Carter H., Kamiyama H., Jimeno A., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
14. Kandoth C., McLellan M.D., Vandin F., Ye K., Niu B., Lu C., Xie M., Zhang Q., McMichael J.F., Wyczalkowski M.A., et al. Mutational landscape and significance across 12 major cancer types. Nature 2013, 502:333-339.
15. Maertens O., Johnson B., Hollstein P., Frederick D.T., Cooper Z.A., Messiaen L., Bronson R.T., McMahon M., Granter S., Flaherty K., et al. Elucidating distinct roles for NF1 in melanomagenesis. Cancer Discov 2013, 3:338-349.
16. Prahallad A., Sun C., Huang S., Di Nicolantonio F., Salazar R., Zecchin D., Beijersbergen R.L., Bardelli A., Bernards R. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 2012, 483:100-103.
17. Schoeberl B., Eichler-Jonsson C., Gilles E.D., Müller G. Computational modeling of the dynamics of the MAP kinase cascade activated by surface and internalized EGF receptors. Nat. Biotechnol. 2002, 20:370-375.
18. Sermon B.A., Lowe P.N., Strom M., Eccleston J.F. The importance of two conserved arginine residues for catalysis by the ras GTPase-activating protein, neurofibromin. J.Biol. Chem. 1998, 273:9480-9485.
19. Shalem O., Sanjana N.E., Hartenian E., Shi X., Scott D.A., Mikkelsen T.S., Heckl D., Ebert B.L., Root D.E., Doench J.G., Zhang F. Genome-scale CRISPR-Cas9 knockout screening in human cells. Science 2014, 343:84-87.
20. Shapira S., Barkan B., Friedman E., Kloog Y., Stein R. The tumor suppressor neurofibromin confers sensitivity to apoptosis by Ras-dependent and Ras-independent pathways. Cell Death Differ. 2007, 14:895-906.
21. Stenson P.D., Mort M., Ball E.V., Shaw K., Phillips A., Cooper D.N. The Human Gene Mutation Database: building a comprehensive mutation repository for clinical and molecular genetics, diagnostic testing and personalized genomic medicine. Hum. Genet. 2014, 133:1-9.
22. Stites E.C., Ravichandran K.S. Mathematical investigation of how oncogenic ras mutants promote ras signaling. Methods Mol. Biol. 2012, 880:69-85.
23. Stites E.C., Trampont P.C., Ma Z., Ravichandran K.S. Network analysis of oncogenic Ras activation in cancer. Science 2007, 318:463-467.
24. Stratton M.R., Campbell P.J., Futreal P.A. The cancer genome. Nature 2009, 458:719-724.
25. Thomas R.K., Baker A.C., Debiasi R.M., Winckler W., Laframboise T., Lin W.M., Wang M., Feng W., Zander T., MacConaill L., et al. High-throughput oncogene mutation profiling in human cancer. Nat. Genet. 2007, 39:347-351.
26. Tiacci E., Trifonov V., Schiavoni G., Holmes A., Kern W., Martelli M.P., Pucciarini A., Bigerna B., Pacini R., Wells V.A., et al. BRAF mutations in hairy-cell leukemia. N.Engl. J. Med. 2011, 364:2305-2315.
27. Wan P.T., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., Jones C.M., Marshall C.J., Springer C.J., Barford D., Marais R. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867. Cancer Genome Project.
28. Whittaker S.R., Theurillat J.P., Van Allen E., Wagle N., Hsiao J., Cowley G.S., Schadendorf D., Root D.E., Garraway L.A. A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov 2013, 3:350-362.
29. Yaffe M.B. The scientific drunk and the lamppost: massive sequencing efforts in cancer discovery and treatment. Sci. Signal. 2013, 6:pe13.
30. Yates L.R., Campbell P.J. Evolution of the cancer genome. Nat. Rev. Genet. 2012, 13:795-806.
31. Yeang C.H., McCormick F., Levine A. Combinatorial patterns of somatic gene mutations in cancer. FASEB J. 2008, 22:2605-2622.